Ibrexafungerp Citrate
FDA-approved product (tablet, oral), marketed as Brexafemme.
- Registered studies
- 0
- Lab records
- 0
- Pathogens at ≥40%
- 4 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Vulvovaginal candidiasis
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Other antimycotics for systemic use
- Anti-infective classification
- Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J02AX07
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA63.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli49.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae44.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- M. tuberculosis46.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
No evidence found
The registry was searched and no registered study names this medicine.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Ibrexafungerp Citrate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Mometasone FuroateExisting use: Airway obstruction, Allergic rhinitis, Asthma and 5 more51.9% AI-predicted activityagainst MRSA50+ registered studies
- Bazedoxifene AcetateExisting use: Postmenopausal osteoporosis51.9% AI-predicted activityagainst MRSA50+ registered studies
- TucatinibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 6 more51.9% AI-predicted activityagainst MRSA50+ registered studies
- Hydrocortisone Sodium SuccinateExisting use: Adrenal gland disease, Adrenocortical insufficiency, Allergic conjunctivitis and 32 more51.8% AI-predicted activityagainst MRSA50+ registered studies
- TirbanibulinExisting use: Actinic keratosis51.8% AI-predicted activityagainst MRSA20 registered studies
- BrexpiprazoleExisting use: Major depressive disorder, Psychosis, Schizoaffective disorder and 1 more51.8% AI-predicted activityagainst MRSA50+ registered studies
- EfavirenzExisting use: HIV infection, HIV-1 infection, Immunodeficiency disease and 2 more51.8% AI-predicted activityagainst MRSA50+ registered studies
- HaloperidolExisting use: Conduct disorder, Mental or behavioural disorder, Psychosis and 4 more51.8% AI-predicted activityagainst MRSA50+ registered studies
- VamoroloneExisting use: Becker muscular dystrophy, Duchenne muscular dystrophy51.7% AI-predicted activityagainst MRSA12 registered studies
- Delavirdine MesylateExisting use: Viral disease51.7% AI-predicted activityagainst MRSA27 registered studies
- DesoximetasoneExisting use: Psoriasis, Psoriasis vulgaris, Skin disease51.7% AI-predicted activityagainst MRSA10 registered studies
- PrednicarbateExisting use: Allergic conjunctivitis, Allergic rhinitis, Ankylosing spondylitis and 56 more51.7% AI-predicted activityagainst MRSA3 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
No evidence found: the registry was searched and no registered study names this medicine.